Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up period with a good product safety profile Gosselies, Belgium, 14 October...